ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / BCAX
NVCT (37) ZVRA (37) OLMA (29) ANL (46) ⌘ Pro Terminal →

Bicara Therapeutics Inc. (BCAX) — RQD Stock Rating Cockpit

$7.93 -13.14% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $7.73

Bicara Therapeutics Inc. (BCAX) carries a Roarable Rating of E (Strong Sell) with 30/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $604.2M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on BCAX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is BCAX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Bicara Therapeutics Inc. (NASDAQ: BCAX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $7.93 (-13.14% 1D, market cap $604.2M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, BCAX ranks #791 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does BCAX compare to NVCT and ZVRA in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BCAX carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, NVCT (Nuvectis Pharma Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $602.7M) and ZVRA (Zevra Therapeutics Inc.) posts a D- grade (37/100 RQD, P/E 7.4x, ROIC -32.3%, cap $610.5M). Among the 5-stock peer group, ZVRA leads on earnings multiple (7.4x) while ZVRA leads on capital efficiency (-32.3% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for BCAX?
▼

Per BCAX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002023658), Bicara Therapeutics Inc. generated $435.7M in revenue (+88.9% YoY), -$137.9M in net income, and -$107.1M in free cash flow against $431.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $7.73 (-2.56%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (30/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.6% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510030
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D-
Cash (8)Whales (4)SEC (10)Macro (5)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-12.6% Base Target
$33 Bull$7 Base$5 Bear
📬 FREE BCAX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BCAX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (30/100 Composite)
🔍 WHY BCAX SCORES 30/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (33% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Cash Engine Quality+8/20 pts (27% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
38
Grade E$17.34+5.8% Next Q
Q2 (-2Q)
35
Grade E$18.35-4.7% Next Q
Q3 (-1Q)
33
Grade E$17.48-54.6% Next Q
Current
30
Grade E$7.93-9.6% Hist 90D α
Trajectory: E (38) → E (30)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a BCAX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While BCAX currently carries a cautious 30/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($19.17) and Max Pain ($8.33) forces dealer call-delta covering toward $32.54.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BCAX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “BCAX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 30%NO 70%Trade / Inspect Odds →
RSI-14 MOMENTUMOVERSOLD (<32)
20.530 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
2 / 99-Pt Accounting
52-WEEK LASER RANGE2% OF RANGE
L: $8$7.93H: $31
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 8 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 7 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D-RQD 15 / 40
MULTI-MODEL QUANT PANEL DELIBERATION

3-of-3 Quant Analysts Bearish Warning on BCAX

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (40)

-35.0% ROIC with 42.0% gross margin and -16.64% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (50)

Altman-Z 4.20 and Piotroski 2/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (20)

7/40 institutional & smart-money positioning score with 5/20 macro alignment.

Bull Case: Why Buyers Like BCAX
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BCAX)

  • ✓Walkthrough of BCAX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
BCAX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -65.10%▼ SUPPORT BREAKDOWN
2026-11-03O $9.73H $9.73L $7.93C $7.93VOL 4.20M
RES: $17.28SUP: $12.80SMA50: $19.17SMA200: $21.13
$32.60$25.92$19.23$12.54$5.85RES $17.28SUP $12.80$7.932026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BCAX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BCAX Butterfly Map → + Track BCAX →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +88.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on BCAX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BCAX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for BCAX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BCAX)

Health Care Rank #791 of 1015 ⚔️ NVCT vs BCAX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BCAX vs. NVCT, ZVRA, OLMA, ANL)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Bicara Therapeutics Inc. (BCAX) ranks #791 by composite RQD confidence (30/100, grade E) and #414 by equity capitalization ($604.2M). Within this direct 5-issuer industry benchmark cohort, ZVRA leads on earnings valuation at 7.4x trailing P/E, while ZVRA leads on capital efficiency and profitability with -32.3% ROIC and — gross margin. ANL currently holds the highest overall quantitative score in the immediate peer group at 46/100 (D) compared with BCAX at 30/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
BCAX ACTIVE
Bicara Therapeutics Inc.
E 30/100 — — -35.0% -13.14% $604.2M Benchmark Subject
NVCT
Nuvectis Pharma Inc.
D- 37/100 — — -35.0% +3.79% $602.7M /nvct-vs-bcax →
ZVRA
Zevra Therapeutics Inc.
D- 37/100 7.4x — -32.3% -1.75% $610.5M /zvra-vs-bcax →
OLMA
Olema Pharmaceuticals Inc.
E 29/100 — — -32.8% +1.00% $612.5M /olma-vs-bcax →
ANL
Adlai Nortye Group Ltd.
D 46/100 — — — -1.88% $615.0M /anl-vs-bcax →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002023658 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Bicara Therapeutics Inc. (BCAX) reported GAAP revenue of $435.7M (+88.9% vs. FY2024 revenue of $230.7M , and +290.1% cumulative change since FY2023) , GAAP net income of -$137.9M, operating cash flow of -$106.8M, and free cash flow of -$107.1M (-43.2% YoY). On the balance sheet, BCAX closed FY2025 with $431.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $435.7M -$137.9M -$106.8M -$107.1M $431.0M —
FY2024 (FY) 2024-12-31 $230.7M -$68.0M -$74.8M -$74.8M $510.0M —
FY2023 (FY) 2023-12-31 $111.7M -$52.0M -$45.6M -$45.6M — —

3. BCAX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BCAX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Bicara Therapeutics Inc. (NASDAQ: BCAX) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 30/100 at a spot price of $7.93 (-13.14% 1D, market cap $604.2M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, BCAX ranks #791 in composite RQD confidence.

How does BCAX compare to NVCT and ZVRA in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BCAX carries a Roarable E (30/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, NVCT (Nuvectis Pharma Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $602.7M) and ZVRA (Zevra Therapeutics Inc.) posts a D- grade (37/100 RQD, P/E 7.4x, ROIC -32.3%, cap $610.5M). Among the 5-stock peer group, ZVRA leads on earnings multiple (7.4x) while ZVRA leads on capital efficiency (-32.3% ROIC).

What are the biggest fundamental strengths and SEC risk factors for BCAX?

Per BCAX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002023658), Bicara Therapeutics Inc. generated $435.7M in revenue (+88.9% YoY), -$137.9M in net income, and -$107.1M in free cash flow against $431.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is BCAX trading relative to its 50-day, 200-day, and 52-week technical levels?

BCAX last traded at $7.93 (-13.14% on volume of 2,503,491 shares), positioning the stock -58.63% below its 50-day simple moving average ($19.17) and -62.47% below its 200-day simple moving average ($21.13). Across its 52-week range of $8.36 to $30.99, BCAX sits at the 0.0% percentile with a 14-day RSI of 20.5 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($6.94 to $8.92).

Direct Sub-Reports: BCAX RQD Cockpit BCAX 12M Forecast BCAX Earnings & Move BCAX Dividends & DRIP BCAX Insiders & 13F BCAX Whale Options BCAX Profit Sankey BCAX News & Why
ROARABLE RATING BRIEF • RQD 30/100 (E) ✓ SEC XBRL & RQD VERIFIED

BCAX — Bicara Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Bicara Therapeutics Inc. (BCAX) earns a live Roarable RQD composite score of 30/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $7.93 (-13.14% 1D, market capitalization $604.2M).

  • Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of -16.64%.
  • Whale 13F & Options Flow (4/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (5/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Bicara Therapeutics Inc. (BCAX) is a NASDAQ-listed operating company in the Biotechnology: Pharmaceutical Preparations industry (Health Care sector) with an equity market capitalization of $604.2M. The business operates with a gross margin of 0%, an operating margin of 0%, and a return on invested capital (ROIC) of -35% (free cash flow yield of -16.64%). Within the Biotechnology: Pharmaceutical Preparations peer group, investor evaluation centers on operating leverage, unit margin durability, and capital allocation efficiency across market cycles.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Bicara Therapeutics Inc. (BCAX) reported $435.7M in annual revenue (up from $230.7M in FY2024, +88.9% YoY) and -$137.9M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($111.7M revenue, -$52.0M net income) through FY2025, BCAX scaled operating cash flow to -$106.8M and free cash flow to -$107.1M, backed by $431.0M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 30/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -16.64% and institutional whale pillar of 4/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 4/20, sustained execution supports upside toward the upper end of the $8.36 – $30.99 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), BCAX carries a macro regime beta of 1.00 and gross margin of —.

  • Key Question #1: Can BCAX sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $435.7M and free cash flow of -$107.1M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is BCAX's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

BCAX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Bicara Therapeutics Inc. (BCAX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to BCAX Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

BCAX Bull vs. Bear Conversation Board — What's Your Call at $7.93?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BCAX 🐻 33% BEARISH CONVICTION
1. Pick Your Side on BCAX:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MA MacroHawk_NYC RQD DEBATE OPENER • Cross-Asset Macro Desk 🐂 BULLISH 🎯 Target: $11.78 (+29.0%)
📌 Pinned Debate

Reported cash of $96.7M and a Forensic Balance Sheet pillar score of 10/20 with Debt/Equity at 0.5 show a balance sheet that is not the

The street is overcomplicating Bicara Therapeutics Inc. (BCAX). Reported cash of $96.7M and a Forensic Balance Sheet pillar score of 10/20 with Debt/Equity at 0.5 show a balance sheet that is not the primary source of distress.. With an RQD score of 30/100 (E) and Forensic Balance Sheet at 10/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $9.86.

VolSurface_Trader 🐂 BULL

@RiskArb_Desk Shorting a 4/20 institutional whale-flow stock at $9.13 is dangerous when funds are rotating into Health Care.

RI RiskArb_Desk RQD DEBATE OPENER • Hedged Event Driven 🐻 BEARISH 🎯 Target: $7.30 (-20.0%)
Spot @ $9.13

ROIC of -35% and FCF of -$107.1M in FY 2025, with cash down from $489.7M, indicate sustained capital consumption without reported reven

Careful chasing BCAX at $9.13. ROIC of -35% and FCF of -$107.1M in FY 2025, with cash down from $489.7M, indicate sustained capital consumption without reported revenue.. Gross margin is 0.0%, but operating margin is 0.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $7.30 on multiple compression.

LIVE TAPE